ArticleNaunyn-Schmiedeberg's archives of pharmacology2025
Therapeutic efficacy of baicalein and 6-(methylsulfinyl)hexyl isothiocyanate, alone or in combination with 5-fluorouracil, in the treatment of colorectal cancer.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is the third most common malignancy worldwide. 5-fluorouracil (5-FU) remains the first-line drug for treatment of the metastatic stage despite the limits of its efficacy. Here, we investigated the anti-tumor effect of two phytochemicals, baicalein and 6-(methylsulfinyl)hexyl isothiocyanate (6-MITC), on colorectal cancer cells (HCT-116 and RKO) and determined whether these individual agents, when used alone or in combination with 5-FU, could enhance treatment efficacy. The evaluations included assays that measure cell viability and proliferation (MTT), apoptosis, cell migration, cell cycle, gelatin zymography, and combination index analyses. In both cell lines, baicalein [HCT-116 cells; IC50 = 40.82 ± 7.77 μM (24 h) and 33.83 ± 1.99 μM (48 h), and RKO cells; IC50 = 55.84 ± 3.12 μM (24 h) and 45.11 ± 3.05 μM (48 h)] and 6-MITC [HCT-116 cells; IC50 = 24.66 ± 1.57 μM (24 h) and 8.28 ± 0.56 μM (48 h), and RKO cells; IC50 = 45.74 ± 1.63 μM (24 h) and 9.85 ± 1.42 (48 h) μM] suppressed cancer cell proliferation in a dose-dependent manner at 24 and 48 h, while 5-FU was cytotoxic only after 48 h [HCT-116 cells; IC50 18.43 ± 3.82, and RKO cells; IC50 = 30.57 ± 8.34 μM]. Compared with 5-FU treatment only, the combined treatments induced significant increases in the pre-G1 phase and decreases in the G1 and S phases in both cell lines. In HCT-116 cells, combined treatments induced significantly greater apoptosis compared to 5-FU alone. Single and combination treatments with baicalein or 6-MITC significantly lowered the migration of cells compared to 5-FU alone in both cell lines. In conclusion, our study showed that both baicalein and 6-MITC induced similar anti-tumor effects compared to 5-FU alone in both cell lines, however, the combined treatments were more efficient.
Indexed as
Identifiers
40493247What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.